Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 3,073 shares, a drop of 80.1% from the November 30th total of 15,433 shares. Based on an average daily volume of 282,575 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 282,575 shares, the days-to-cover ratio is presently 0.0 days.
Analyst Ratings Changes
A number of research firms recently issued reports on SAUHY. Citigroup reiterated a “sell” rating on shares of Straumann in a research note on Wednesday, October 22nd. The Goldman Sachs Group downgraded Straumann from a “strong-buy” rating to a “neutral” rating in a research report on Monday, October 13th. Deutsche Bank Aktiengesellschaft upgraded Straumann from a “hold” rating to a “buy” rating in a research note on Friday, October 31st. UBS Group upgraded Straumann from a “sell” rating to a “neutral” rating in a report on Tuesday, November 4th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Straumann in a research report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.
Check Out Our Latest Analysis on Straumann
Straumann Trading Down 0.2%
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Further Reading
- Five stocks we like better than Straumann
- Do not delete, read immediately
- Do you know what Amazon is planning for January 1?
- The boring AI play that could pay up to $4,290 monthly
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- Terrifying reason Trump killed the U.S. penny?
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
